<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522689</url>
  </required_header>
  <id_info>
    <org_study_id>SU-PCNL-UMMP-02</org_study_id>
    <nct_id>NCT02522689</nct_id>
  </id_info>
  <brief_title>Comparison of Ultra-mini PCNL and Micro PCNL</brief_title>
  <official_title>Comparison of Success Rates, Complication Rates and Injury to Kidneys of Ultra-mini PCNL and Micro PCNL in the Treatment of Kidney Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selcuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Scientific and Technological Research Council of Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Selcuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is aimed to evaluate the treatment results, rates of success and complications, and injury
      given to the kidney by measuring preoperative and postoperative blood and Cystatin C levels
      in patients with kidney stones smaller than 2 cm who will undergo either ultra-mini
      percutaneous nephrolithotripsy (PCNL) or micro PCNL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the demographic and preoperative data, imaging data, operative data and
      postoperative follow-up data will be prospectively recorded according to the patient
      information forms for the patients with kidney stone smaller than 2 cm who will undergo
      either ultra-mini PCNL or micro PCNL.

      A total of 60 (sixty) patients, aging between 18 and 65 years, with similar stone size and
      location are being planned to be enrolled into the study; and will be prospectively
      randomized into two groups with a 1:1 ratio, thus 30 (thirty) patients will receive
      ultra-mini PCNL while 30 (thirty) patients will undergo micro PCNL.

      Preoperatively, blood and urine Cystatin C levels will be measured. After the surgery, blood
      and urine Cystatin C levels at postoperative 12th hour will be recorded. Besides these,
      classical kidney function tests, namely blood urea and creatinine levels, will be measured
      preoperatively and postoperatively.

      Parameters listed below will be also recorded and evaluated:

        1. Preoperative general evaluation data: Age, height, weight, body-mass index, concomitant
           comorbidities, prescriptions used, history of operation(s), American Society of
           Anesthesiologists (ASA) score

        2. Preoperative urological evaluation data: History of extracorporeal shock wave
           lithotripsy (ESWL)/PCNL/ureterorenoscopy (URS)/retrograde intrarenal surgery (RIRS)/open
           surgery, whole blood count, kidney function tests, automatic urine test, urine culture,
           preoperative imaging modality (KUB, US, CT), number-dimensions-localization-composition
           of stone(s), existence of hydronephrosis

        3. Operative data: Access fluoroscopy duration, total access duration, total fluoroscopy
           duration, operation duration, use of double-J stent, preoperative complications

        4. Number of previous ESWL seance, total duration of ESWL, number of shots during ESWL (if
           any)

        5. Follow-up data: Urethral catheterization time, hospitalization time, need of any other
           treatment for being stone-free, time to full stone-free, duration to removal of double-J
           stent, existence of residual stone(s), formation of new stone(s), complications in late
           period
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stone-free rate</measure>
    <time_frame>Within the first 30 days after surgery.</time_frame>
    <description>Determination of any residual stone in the collecting system by using one of imaging modalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>Within the first 30 days after surgery.</time_frame>
    <description>Determination of any complications related to the surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Cystatin C level (mg/L)</measure>
    <time_frame>Within the first 12 hours after surgery.</time_frame>
    <description>Determination of any impairment in renal function after the surgery/procedure by measuring blood Cystatin C level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Cystatin C level (mg/L)</measure>
    <time_frame>Within the first 12 hours after surgery.</time_frame>
    <description>Determination of any impairment in renal function after the surgery/procedure by measuring urine Cystatin C level.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Ultra-mini PCNL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micro PCNL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic kidney stone surgery</intervention_name>
    <description>Ultra-mini PCNL will be performed.</description>
    <arm_group_label>Ultra-mini PCNL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic kidney stone surgery</intervention_name>
    <description>Micro PCNL will be performed.</description>
    <arm_group_label>Micro PCNL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are planned to undergo PCNL due to kidney stone

          -  Patients with a kidney stone &lt; 2 cm

          -  Patients between 18 and 65 years old

        Exclusion Criteria:

          -  Patients with unregulated diabetes mellitus and diabetic nephropathy

          -  Patients with a blood pressure higher than 140/80 mmHg despite use of antihypertensive
             drug(s) regularly

          -  Patients with chronic renal failure who need dialysis

          -  Patients who had prerenal, renal or postrenal acute kidney failure during the last 6
             months

          -  Patients who had acute pyelonephritis during the last 6 months

          -  Patients younger than 18 years old or older than 65 years old

          -  Patients who had kidney surgery during the last 3 months and who have abnormal kidney
             functions

          -  Patients with ureteral stone who are planned to undergo endoscopic stone treatment at
             the same time

          -  Patients with a history of corticosteroid use during enrollment into the study or
             previous 3 months

          -  Patients with uncontrolled thyroid disease

          -  Patients who have a disease with rapid cell turn-over (like leukemia, lymphoma, etc.)

          -  Patients whose operation terminated or converted to open surgery due to any reason

          -  Patients with missing data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ozcan Kilic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Selcuk University, School of Medicine, Department of Urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ozcan Kilic, M.D.</last_name>
    <phone>+905074196189</phone>
    <email>drozcankilic@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murat Akand, M.D.</last_name>
    <phone>+905327438333</phone>
    <email>drmuratakand@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Selcuk University, School of Medicine, Department of Urology</name>
      <address>
        <city>Konya</city>
        <zip>42075</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ozcan Kilic, M.D.</last_name>
      <phone>+905074196189</phone>
      <email>drozcankilic@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Murat Akand, M.D.</last_name>
      <phone>+905327438333</phone>
      <email>drmuratakand@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>de la Rosette J, Assimos D, Desai M, Gutierrez J, Lingeman J, Scarpa R, Tefekli A; CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. J Endourol. 2011 Jan;25(1):11-7. doi: 10.1089/end.2010.0424.</citation>
    <PMID>21247286</PMID>
  </reference>
  <reference>
    <citation>Xu S, Shi H, Zhu J, Wang Y, Cao Y, Li K, Wang Y, Sun Z, Xia S. A prospective comparative study of haemodynamic, electrolyte, and metabolic changes during percutaneous nephrolithotomy and minimally invasive percutaneous nephrolithotomy. World J Urol. 2014 Oct;32(5):1275-80. doi: 10.1007/s00345-013-1204-2. Epub 2013 Nov 1.</citation>
    <PMID>24177788</PMID>
  </reference>
  <reference>
    <citation>Wong KA, Sahai A, Patel A, Thomas K, Bultitude M, Glass J. Is percutaneous nephrolithotomy in solitary kidneys safe? Urology. 2013 Nov;82(5):1013-6. doi: 10.1016/j.urology.2013.06.034. Epub 2013 Aug 16.</citation>
    <PMID>23958507</PMID>
  </reference>
  <reference>
    <citation>Kamphuis GM, Baard J, Westendarp M, de la Rosette JJ. Lessons learned from the CROES percutaneous nephrolithotomy global study. World J Urol. 2015 Feb;33(2):223-33. doi: 10.1007/s00345-014-1367-5. Epub 2014 Aug 7.</citation>
    <PMID>25100624</PMID>
  </reference>
  <reference>
    <citation>De S, Autorino R, Kim FJ, Zargar H, Laydner H, Balsamo R, Torricelli FC, Di Palma C, Molina WR, Monga M, De Sio M. Percutaneous nephrolithotomy versus retrograde intrarenal surgery: a systematic review and meta-analysis. Eur Urol. 2015 Jan;67(1):125-137. doi: 10.1016/j.eururo.2014.07.003. Epub 2014 Jul 23. Review. Erratum in: Eur Urol. 2016 Apr;69(4):e85.</citation>
    <PMID>25064687</PMID>
  </reference>
  <reference>
    <citation>Bader MJ, Gratzke C, Seitz M, Sharma R, Stief CG, Desai M. The &quot;all-seeing needle&quot;: initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol. 2011 Jun;59(6):1054-9. doi: 10.1016/j.eururo.2011.03.026. Epub 2011 Apr 1.</citation>
    <PMID>21477921</PMID>
  </reference>
  <reference>
    <citation>Desai MR, Sharma R, Mishra S, Sabnis RB, Stief C, Bader M. Single-step percutaneous nephrolithotomy (microperc): the initial clinical report. J Urol. 2011 Jul;186(1):140-5. doi: 10.1016/j.juro.2011.03.029. Epub 2011 May 14.</citation>
    <PMID>21575966</PMID>
  </reference>
  <reference>
    <citation>Hatipoglu NK, Tepeler A, Buldu I, Atis G, Bodakci MN, Sancaktutar AA, Silay MS, Daggulli M, Istanbulluoglu MO, Karatag T, Gurbuz C, Armagan A, Caskurlu T. Initial experience of micro-percutaneous nephrolithotomy in the treatment of renal calculi in 140 renal units. Urolithiasis. 2014 Apr;42(2):159-64. doi: 10.1007/s00240-013-0631-2. Epub 2013 Dec 13.</citation>
    <PMID>24337646</PMID>
  </reference>
  <reference>
    <citation>Karatag T, Tepeler A, Buldu I, Akcay M, Tosun M, Istanbulluoglu MO, Armagan A. Is micro-percutaneous nephrolithotomy surgery technically feasible and efficient under spinal anesthesia? Urolithiasis. 2015 Jun;43(3):249-54. doi: 10.1007/s00240-015-0752-x. Epub 2015 Jan 9.</citation>
    <PMID>25572955</PMID>
  </reference>
  <reference>
    <citation>Desai J, Solanki R. Ultra-mini percutaneous nephrolithotomy (UMP): one more armamentarium. BJU Int. 2013 Nov;112(7):1046-9. doi: 10.1111/bju.12193. Epub 2013 Jul 11.</citation>
    <PMID>23841665</PMID>
  </reference>
  <reference>
    <citation>Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013 Sep;62(3):595-603. doi: 10.1053/j.ajkd.2013.03.027. Epub 2013 May 20. Review.</citation>
    <PMID>23701892</PMID>
  </reference>
  <reference>
    <citation>Delanaye P, Cavalier E, Morel J, Mehdi M, Maillard N, Claisse G, Lambermont B, Dubois BE, Damas P, Krzesinski JM, Lautrette A, Mariat C. Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine. BMC Nephrol. 2014 Jan 13;15:9. doi: 10.1186/1471-2369-15-9.</citation>
    <PMID>24410757</PMID>
  </reference>
  <reference>
    <citation>Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. Clin J Am Soc Nephrol. 2010 Sep;5(9):1552-7. doi: 10.2215/CJN.02040310. Epub 2010 Jun 10.</citation>
    <PMID>20538834</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Selcuk University</investigator_affiliation>
    <investigator_full_name>Ozcan Kilic</investigator_full_name>
    <investigator_title>M.D., Assoc. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>kidney stone</keyword>
  <keyword>percutaneous nephrolithotripsy</keyword>
  <keyword>ultra-mini PCNL</keyword>
  <keyword>micro PCNL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

